Page last updated: 2024-11-08

cantharidin and Pain

cantharidin has been researched along with Pain in 12 studies

Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy."9.41Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021)
"Topical cantharidin demonstrated clearance of warts, particularly in combination with podophyllotixin and salicylic acid, and modest benefit for pediatric molluscum contagiosum with good tolerability and safety."8.98Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. ( Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018)
"The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum."7.75Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. ( Cathcart, S; Coloe, J; Morrell, DS, 2009)
"Seventy-six digital and periungual warts in 40 patients were treated topically with cantharidin, a potent blistering agent."7.64Cantharidin treatment of digital and periungual warts. ( EPSTEIN, JH; EPSTEIN, WL, 1960)
" Safety outcomes included assessment of adverse events, including expected local skin reactions."6.94Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020)
"Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy."5.41Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021)
"Topical cantharidin demonstrated clearance of warts, particularly in combination with podophyllotixin and salicylic acid, and modest benefit for pediatric molluscum contagiosum with good tolerability and safety."4.98Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. ( Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018)
"A PubMed search was conducted using the term "cantharidin" combined with "warts", "plantar warts", "verruca vulgaris", "periungal", "subungual", "topical treatment", "topical therapy for warts", molluscum contagiosum", "perforating collagenosis," and "acantholysis."4.90Cantharidin: a comprehensive review of the clinical literature. ( DeMoll, E; Levitt, J; Pan, M; Torbeck, R, 2014)
"The results contribute to the data supporting cantharidin as a safe and effective treatment of molluscum contagiosum."3.75Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. ( Cathcart, S; Coloe, J; Morrell, DS, 2009)
"Seventy-six digital and periungual warts in 40 patients were treated topically with cantharidin, a potent blistering agent."3.64Cantharidin treatment of digital and periungual warts. ( EPSTEIN, JH; EPSTEIN, WL, 1960)
" Safety outcomes included assessment of adverse events, including expected local skin reactions."2.94Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19904 (33.33)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's2 (16.67)24.3611
2020's3 (25.00)2.80

Authors

AuthorsStudies
Eichenfield, LF2
McFalda, W1
Brabec, B1
Siegfried, E2
Kwong, P2
McBride, M2
Rieger, J2
Willson, C2
Davidson, M2
Burnett, P2
Glover, D1
Olivadoti, M1
Cotton, CH1
Vakharia, PP1
Chopra, R1
Silverberg, NB2
Silverberg, JI1
Torbeck, R1
Pan, M1
DeMoll, E1
Levitt, J1
Cathcart, S1
Coloe, J1
Morrell, DS1
Moncada, A1
Cendán, CM1
Baeyens, JM1
Del Pozo, E1
EPSTEIN, JH1
EPSTEIN, WL1
SCHARFBILLIG, C1
Sidbury, R1
Mancini, AJ1
Chiarini, P2
Matassi, L2
Fabrizi, G1
Galletti, R1
Corti, F1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377803]Phase 3262 participants (Actual)Interventional2018-02-14Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377790]Phase 3266 participants (Actual)Interventional2018-03-21Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionchange in wart count from baseline (Mean)
VP-102-17.1
Placebo-10.9

Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit

Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionpercentage change from Baseline (Mean)
VP-102-83.3
Placebo-19.1

Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Percentage of subjects exhibiting a 75% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84(EOS)

InterventionParticipants (Count of Participants)
VP-102122
Placebo40

Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit

Percentage of subjects exhibiting a 90% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-102105
Placebo31

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 21

InterventionParticipants (Count of Participants)
VP-1028
Placebo2

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 42

InterventionParticipants (Count of Participants)
VP-10219
Placebo4

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 63

InterventionParticipants (Count of Participants)
VP-10242
Placebo5

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10281
Placebo15

Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject

Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. (NCT03377803)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).

InterventionParticipants (Count of Participants)
VP-10210
Placebo7

Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age

"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377803)
Timeframe: Day 1 (Baseline), 21, 42, 63 and Day 84 (EOS)

,
Interventionscore on a scale (Mean)
Day 21Day 42Day 63Day 84 (EOS)
Placebo-1.2-1.4-1.6-1.9
VP-102-1.0-1.5-2.0-2.1

Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionchange in wart count (Mean)
VP-102-18.3
Placebo-5.9

Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.

"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377790)
Timeframe: Baseline to Day 84 (EOS)

Interventionunits on a scale (Mean)
VP-102-2.1
Placebo-2.7

Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit

Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

Interventionpercentage of change in wart count (Mean)
VP-102-69.2
Placebo20.0

Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-102119
Placebo36

Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.

Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10299
Placebo28

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 42

InterventionParticipants (Count of Participants)
VP-10233
Placebo10

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 63

InterventionParticipants (Count of Participants)
VP-10251
Placebo18

Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)

Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 84 (EOS)

InterventionParticipants (Count of Participants)
VP-10274
Placebo19

Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit

Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 21

InterventionParticipants (Count of Participants)
VP-10218
Placebo4

Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject.

Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. (NCT03377790)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).

InterventionParticipants (Count of Participants)
VP-1029
Placebo13

Reviews

2 reviews available for cantharidin and Pain

ArticleYear
Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
    American journal of clinical dermatology, 2018, Volume: 19, Issue:6

    Topics: Administration, Cutaneous; Blister; Cantharidin; Drug Therapy, Combination; Humans; Incidence; Irrit

2018
Cantharidin: a comprehensive review of the clinical literature.
    Dermatology online journal, 2014, Jun-15, Volume: 20, Issue:6

    Topics: Administration, Topical; Blister; Cantharidin; Erythema; Humans; Molluscum Contagiosum; Pain; Warts

2014

Trials

3 trials available for cantharidin and Pain

ArticleYear
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr

2020
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr

2020
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr

2020
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr

2020
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:2

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq

2021
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:2

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq

2021
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:2

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq

2021
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    American journal of clinical dermatology, 2021, Volume: 22, Issue:2

    Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq

2021
Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients.
    Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:3

    Topics: Blister; Cantharidin; Child; Child, Preschool; Erythema; Female; Humans; Irritants; Male; Molluscum

2000

Other Studies

7 other studies available for cantharidin and Pain

ArticleYear
Pediatric Game Changers∗: Cantharidin for treatment of facial molluscum contagiosum: A retrospective review.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:6

    Topics: Cantharidin; Child; Humans; Molluscum Contagiosum; Pain; Retrospective Studies; Treatment Outcome

2021
Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection.
    Clinical pediatrics, 2009, Volume: 48, Issue:2

    Topics: Adolescent; Cantharidin; Child; Child, Preschool; Cross-Sectional Studies; Enzyme Inhibitors; Female

2009
Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice.
    European journal of pharmacology, 2003, Mar-28, Volume: 465, Issue:1-2

    Topics: Analgesics, Opioid; Animals; Binding, Competitive; Cantharidin; Dose-Response Relationship, Drug; En

2003
Cantharidin treatment of digital and periungual warts.
    California medicine, 1960, Volume: 93

    Topics: Blister; Cantharidin; Child; Humans; Nail Diseases; Pain; Papilloma; Warts

1960
[Relief of pain by diversion of the stimulus].
    Hippokrates, 1950, May-30, Volume: 21, Issue:10

    Topics: Cantharidin; Gallbladder; Humans; Pain; Physiological Phenomena

1950
[Calcitonin and somatic pain: influence of the hormone on the algogenic component of experimental cantharidin-induced cutaneous inflammation].
    La Clinica terapeutica, 1978, Sep-15, Volume: 86, Issue:5

    Topics: Calcitonin; Cantharidin; Humans; Inflammation; Pain

1978
Action of U.V. rays on the the experimental cutaneous inflammation induced by cantharidin.
    Advances in experimental medicine and biology, 1976, Volume: 70, Issue:00

    Topics: Cantharidin; Dermatitis, Contact; Histamine; Humans; Inflammation; Pain; Radiation Effects; Time Fac

1976